Clinical effects of pulmonary surfactant in combination with nasal continuous positive airway pressure therapy on neonatal respiratory distress syndrome

Zhang, Congmin; Zhu, Xun

doi:10.12669/pjms.333.12227

Cited by 8 publications

(5 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…If the oxygen concentration was >80%, the pressure was >6-7 cmH 2 O, and the oxygen saturation was still <85% after 6-8 hours of treatment, or type II respiratory failure occurred, the treatment method was changed to mechanical ventilation. On the basis of the above, neonates in the observation group were injected with exogenous PS [17] into trachea as soon as possible.…”

Section: Inclusion and Exclusionmentioning

confidence: 99%

[Retracted] Effects of Pulmonary Surfactant Combined with Noninvasive Positive Pressure Ventilation on KRT‐14 and ET‐1 Levels in Peripheral Blood and Therapeutic Effects in Neonates with Respiratory Distress Syndrome

Li-han

Hong

Liu

et al. 2021

BioMed Research International

View full text Add to dashboard Cite

This study is aimed at exploring the effect of pulmonary surfactant (PS) combined with noninvasive positive pressure ventilation on the levels of Keratin-14 (KRT-14) and Endothelin-1 (ET-1) in peripheral blood and the therapeutic effect of neonatal respiratory distress syndrome (NRDS). Altogether 137 cases of neonates with respiratory distress syndrome treated in our hospital from April 2016 to July 2018 were collected. Among them, 64 cases treated with noninvasive positive pressure ventilation were considered as the control group, and 73 cases treated with PS combined with noninvasive positive pressure ventilation were considered as the observation group. The expression of KRT-14 and ET-1 in the two groups was compared. The therapeutic effect, death, complications, and blood gas indexes PaO2, PaCO2, and PaO2/FiO2 in the two groups were compared. Receiver operating characteristic curve (ROC) was applied to analyze the diagnostic value of KRT-14 and ET-1 in the therapeutic effect of NRDS. The effective rate of the observation group was higher than that of the control group. After treatment, PaO2 and PaO2/FiO2 in both groups were notably higher than that before treatment, while PaCO2 was notably lower than that before treatment. And after treatment, the levels of PaO2 and PaO2/FiO2 in the observation group were remarkably higher than that in the control group; PaCO2 was notably lower than that in the control group. After treatment, the levels of KRT-14 and ET-1 in the two groups were remarkably lower than those before treatment, and the levels of KRT-14 and ET-1 in the observation group were considerably lower than those in the control group after treatment. ROC curve showed that the area under the curve (AUC) of KRT-14 was 0.791, and the AUC of ET-1 was 0.816. PS combined with noninvasive positive pressure ventilation can notably improve the therapeutic effect of NRDS. KRT-14 and ET-1 levels may be potential therapeutic diagnostic indicators.

show abstract

Section: Inclusion and Exclusionmentioning

confidence: 99%

[Retracted] Effects of Pulmonary Surfactant Combined with Noninvasive Positive Pressure Ventilation on KRT‐14 and ET‐1 Levels in Peripheral Blood and Therapeutic Effects in Neonates with Respiratory Distress Syndrome

Li-han

Hong

Liu

et al. 2021

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…After Curosurf enters the airway, it is absorbed by the liquid-gel layer, so bucking and other discomfort do not occur easily, the pulmonary compliance and pulmonary oxygen saturation can be increased, and the pulmonary capacity and functional residual capacity can be improved, thus, promoting the pulmonary respiratory function (13). Curosurf treatment seldom causes bucking and other discomfort in child patients, with rapid onset and long-term action, which, according to the research of some scholars, has an excellent therapeutic effect on NRDS (14,15). Ambroxol hydrochloride, also known as ambrotherxol hydrochloride, is a kind of mucolytic and an active metabolite of bromhexine in the body, which can specifically bind to lung tissues, stimulate the phospholipid synthesis, reduce the generation of hydrogen peroxide and superoxide anion, promote the generation and secretion of pulmonary surfactant, reduce lung damage, alleviate the inflammatory response, attenuate alveolar epithelial cell damage, relieve pulmonary edema and decrease pulmonary interstitial exudation.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of pulmonary surfactant combined with high-dose ambroxol hydrochloride in the treatment of neonatal respiratory distress syndrome

Xiang

Wang

2019

Exp Ther Med

View full text Add to dashboard Cite

Clinical efficacy of pulmonary surfactant combined with high-dose ambroxol hydrochloride in the treatment of neonatal respiratory distress syndrome (NRDS) was investigated. One hundred child patients with NRDS in Linyi Central Hospital were collected according to the diagnostic criteria for RDS in the Pediatrics, and randomly divided into the treatment group (n=50) and the control group (n=50) based on different therapeutic methods. Patients in the control group were treated with basic treatment and high-dose ambroxol hydrochloride injection, while those in the treatment group were additionally administered with pulmonary surfactant Curosurf based on conventional therapy in the control group. The chest X-rays were collected before the treatment and at 12 h after the drug administration, the degree of respiratory distress in child patients was observed and evaluated via Silverman grading, and changes in blood gas indexes were recorded before treatment and at 2, 6 and 12 h after the drug administration. The chest X-ray grade, Silverman grade and blood gas analysis results had no differences between the two groups before the treatment (P>0.05). In the treatment group, partial pressure of oxygen (PaO 2 ) and PH were increased and partial pressure of carbon dioxide (PaCO 2 ) was decreased compared with those in the control group at 2, 6 and 12 h after the drug administration (P<0.05). At 12 h after the drug administration, chest X-ray grade and Silverman grade in both groups were improved, which were significantly superior in the treatment group to those in the control group (P<0.01). Moreover, the efficacy in the treatment group was remarkably better than that in the control group at 12 h after drug administration (P<0.01). Pulmonary surfactant combined with high-dose ambroxol hydrochloride has definite efficacy in the treatment of NRDS, which can significantly improve the pulmonary infection, respiratory distress and blood gas indexes of child patients.

show abstract

“…The study was approved by the Institutional Review Board of UCHS (Ref: 2021-293-CHICH, Dated: 11-06-2021) and informed and written consent was obtained from a parent/guardian. Neonates less than 34 weeks of gestation having respiratory distress, that worsened on nCPAP with FIO 2 >30 % and 6cm H 2 O pressure 7 were included. We did not include babies who were intubated in the delivery room or had birth asphyxia.…”

Section: Methodsmentioning

confidence: 99%

“…6 Multiple strategies such as antenatal steroids, surfactant administration, oxygenation and nasal CPAP have improved the outcome of respiratory distress syndrome. 7,8 Surfactant administration alone has lessened mortalities from RDS by 50%. 9 Currently, different methods of surfactant instillation are in use such as INSURE (INtubation, SURfactant administration and Extubation to CPAP), LISA (Less Invasive Surfactant Administration) and MIST (Minimally Invasive Surfactant Therapy).…”

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of surfactant administration by MIST and INSURE techniques in Neonates with Respiratory Distress Syndrome: A randomized controlled trial

Kaleem

Haroon²,

Fatima³

et al. 2023

Pak J Med Sci

View full text Add to dashboard Cite

Objective: To measure the efficacy and safety of surfactant administered by MIST and INSURE to neonates with respiratory distress syndrome. Methods: A randomized controlled trial was conducted from June 2021 to August 2022 at the NICU of the University of Child Health Sciences, Lahore. Neonates meeting inclusion criteria i.e with RDS who worsened on nasal Continuous positive airway pressure (nCPAP) (fiO2 30%, pressure 6cmH2O) were enrolled in the study in both interventional arms (MIST, n=36 and INSURE, n=36) using simple random sampling. Data was analysed using SPSS 25. Results: The mean age of neonates in MIST was 1.27±0.40 days and 1.23±0.48 days in INSURE cohort. Neonates with MIST (n=8) required statistically significant reduced need for IMV than INSURE (n=17) technique (P-Value 0.047). This study could not achieve significant difference in duration of mechanical ventilation (1±1.67; 1.52±1.40 days, P=0.152) and duration of nCPAP (3.27±1.65;3.67±1.64 hrs, P=0.312) in MIST versus INSURE. The second dose of surfactant was administered in fewer cases in MIST (n=2) than INSURE (n=7) (P=0.075). Risk estimation, although not significant, determined less likelihood for the pulmonary haemorrhage (0.908 than 1.095), intraventricular hemorrhage (0.657 than 1.353), administration of the second dose of surfactant (0.412 than 1.690) and greater likelihood of discharge (1.082 than 0.270) at 95% confidence interval with MIST technique. Conclusion: Surfactant therapy through MIST is effective and there is significantly reduced need of IMV than in INSURE. Safety profile though could not achieve statistical significance yet determines less risk of complications associated with MIST than INSURE. doi: https://doi.org/10.12669/pjms.39.3.7283 How to cite this: Kaleem A, Haroon F, Fatima B, Victor G, Qadir M, Waheed KAI. Efficacy and safety of surfactant administration by MIST and INSURE techniques in Neonates with Respiratory Distress Syndrome: A randomized controlled trial. Pak J Med Sci. 2023;39(3):848-852. doi: https://doi.org/10.12669/pjms.39.3.7283 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

show abstract

Clinical effects of pulmonary surfactant in combination with nasal continuous positive airway pressure therapy on neonatal respiratory distress syndrome

Cited by 8 publications

References 14 publications

[Retracted] Effects of Pulmonary Surfactant Combined with Noninvasive Positive Pressure Ventilation on KRT‐14 and ET‐1 Levels in Peripheral Blood and Therapeutic Effects in Neonates with Respiratory Distress Syndrome

[Retracted] Effects of Pulmonary Surfactant Combined with Noninvasive Positive Pressure Ventilation on KRT‐14 and ET‐1 Levels in Peripheral Blood and Therapeutic Effects in Neonates with Respiratory Distress Syndrome

Efficacy of pulmonary surfactant combined with high-dose ambroxol hydrochloride in the treatment of neonatal respiratory distress syndrome

Efficacy and safety of surfactant administration by MIST and INSURE techniques in Neonates with Respiratory Distress Syndrome: A randomized controlled trial

Contact Info

Product

Resources

About